An interventional study of Lactiplantibacillus plantarum RS5- and RI11-Derived Postbiotic Metabolite Supplement in Irritable Bowel Syndrome (IBS), sponsored by My Myracle Sdn.Bhd. Not yet recruiting at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by My Myracle Sdn.Bhd · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.
This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).
The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.
Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.
PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.
Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.
The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.
The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.
Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.
Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.
The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.
1,120 studies on the registry are indexed under Irritable Bowel Syndrome; 211 are open to participants now.
This study's planned enrollment of 55 is below the median of 70 across 899 interventional studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →My Myracle Sdn.Bhd is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis.
Dietary Supplement: Lactiplantibacillus plantarum RS5- and RI11-Derived Postbiotic Metabolite Supplement
PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.
Also known as: PosBion®
Change in Salivary Interleukin-8 (IL-8) Concentration
Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12.
Time frame: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
Change in Salivary Myeloperoxidase (MPO)
Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lactoferrin
Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary Secretory Immunoglobulin A (sIgA)
Salivary sIgA concentration will be quantified as a marker of mucosal immune activity.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgE
Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgM
Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgG
Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.
Time frame: Baseline, Week 4, Week 8, and Week 12
Baseline, Week 4, Week 8, and Week 12
Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary Serotonin
Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary Zonulin
Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lipopolysaccharide (LPS)
Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Salivary LPS-Binding Protein (LBP)
Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products.
Time frame: Baseline, Week 4, Week 8, and Week 12
Plan to share: Yes — De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.
Access criteria: Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 3 months is below that.
Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
My Myracle Sdn.Bhd